The Norovirus Diagnostics Market is slated to grow on a stellar note going forward. The current situation is that digitization, which has the capacity of changing the dynamics of any vertical, has made a beeline to the healthcare vertical. The world out there no more depends on references for choosing healthcare services but goes for 360-degree research before arriving at the final decision. This would be the digitized healthcare vertical in the future.
As per Persistence Market Research’s latest industry analysis, the global norovirus diagnostics market was valued at US$ 47.6 Mn in 2020, and is expected to exhibit a CAGR of around 8.4% over the forecast period (2021-2031).
The norovirus illness is highly contagious, and even a small amount of norovirus virions can induce infection (1-10 virions particles). Currently, only RT-PCR is available for virus detection, which is both, trustworthy and sensitive. However, carrying out these processes is time-consuming and necessitates the use of special equipment. Hence, companies are focused on developing rapid point-of-care (POCT) tests such as biosensors or lateral flow immunoassays for norovirus detection. Increasing demand for rapid tests for the detection of norovirus is expected to propel market growth over the years to come.
Get Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/25924
Key market players are focusing on the development of new diagnostic tests to cater to rising demand in the market.
- For Instance, in December 2020, Altona Diagnostics launched AltoStar Norovirus RT-PCR Kit 1.5. It is an automated in-vitro diagnostic test for the detection of norovirus genogroup I (GI) and II (GII).
The pandemic has had a significant impact on healthcare for conditions such as hypertension, cancer, diabetes management, and cardiovascular emergencies. Change in healthcare professionals’ focus away from these diseases and toward COVID-19 criticality has had a severe influence on the broader healthcare business. However, the market is expected to increase rapidly over the next years.
Company Profiles:
- Abbott
- R-Biopharm AG
- Cepheid
- Luminex Corporation
- Meridian Bioscience
- ELITechGroup
- Biomérieux SA
- CerTest Biotec S.L.
- Elisabeth Pharmacon, Spol. S Ro
- Qiagen
- Altona Diagnostics GmbH
- Eiken Chemical Co.
Request for Methodology@ https://www.persistencemarketresearch.com/methodology/25924
Key Takeaways from Market Study
- Based on product, rapid tests are leading with 56% market share due to their high accuracy and sensitivity.
- Diagnostics laboratories dominate with a market share of 50%.
- By region, North America is set to dominate the global market with a value share of around 32.6%.
- Europe is slated to be the second-largest leading market with a value share of 29% across the forecast period.
- In 2020, Japan dominated the East Asia market with 50%. However, over the forecasted period, the market in China is expected to grow exponentially at a CAGR of 14.1%.
“Increasing prevalence of norovirus infections and rising awareness about testing are expected to drive market growth over the next ten years,” says an analyst of Persistence Market Research.
Access Full Report@ https://www.persistencemarketresearch.com/checkout/25924
Market Competition
Agreements, collaborations, and partnerships have emerged as key growth strategies adopted by industry players. By focusing on these strategies, key stakeholders are expanding their geographic footprints and strengthening their existing product portfolios.
- In August 2016, Danaher Corporation completed the acquisition of Cepheid, a molecular diagnostics company for approximately US$ 4 Bn.
- In April 2020, Meridian Biosciences acquired Exalenz Bioscience for approximately US$ 89 Mn
What Does the Report Cover?
Persistence Market Research offers a unique perspective and actionable insights on the norovirus diagnostics market in its latest study, presenting a historical demand assessment of 2016 – 2020 and projections for 2021 – 2031.
The research study is based on product (rapid test kits, PCR kits, and ELISA-based kits), and end user (hospitals, diagnostics laboratories, and clinics), across seven key regions of the world.
Access Related Reports:
Perineal Care Market
Perineal Care Market is expected to register a CAGR of 4.6% from 2017 to 2025. In 2017, the marker was worth US$ 878.2 Mn and it is expected to reach a valuation of US$ 1,254.8 Mn by the end of 2025.
Hospital Acquired Infection Control Market
Global Hospital Acquired Infection Control market is expected to be valued US$ 55 Bn & expand at a CAGR of 3% during forecast period of 2021-2026.
About us: Persistence Market Research
Contact us:
Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City,
NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com